AngioDynamics closes $55M Vortex buy; Medical device tax repeal could get through Senate;

 @FierceMedDev: JNJ pulled in $7.1 billion from medical devices and diagnostics in Q3, a 12.5% jump. More | Follow @FierceMedDev

 @MarkHFierce: Patients in India thrived with used ICD implants. Can this be done on a broader scale? More | Follow @MarkHFierce

 @DamianFierce: Medtronic is buying a $66.2M stake in China's LifeTech Scientific, makers of cardiovascular devices. More | Follow @DamianFierce

> AngioDynamics ($ANGO) has closed its purchase of Vortex Medical, a deal worth $55 million over five years. News

> Devicemaker ICU Medical posted a third-quarter profit of $12.2 million, a 31% jump over the previous year. Article

> Hologic ($HOLX) picked up FDA approval for its Aptima HPV diagnostic assay, designed for the company's Tigris test platform. More

> HemoSonics is partnering with Cambridge Consultants to finalize the development of a new diagnostic instrument for blood clotting. Item

> A Pennsylvania court dismissed a few of the claims against Stryker ($SYK) over its CerviCore implant, but the company still faces negligence charges. Story

> Thermo Fisher Scientific ($TMO) has launched the MYCEL Imager, an imaging tool designed to capture and analyze protein and nucleic acid gels and Western blots. Release

> There's a chance the effort to repeal the 2.3% excise tax on medical devices could clear the Senate, but it's unlikely to have enough support to overturn the resulting presidential veto. Analysis

Biotech News

 @FierceBiotech: New special report on FierceVaccines.com: 10 promising therapeutic vaccines in 2012. Feature | Follow @FierceBiotech

 @JohnCFierce: Genzyme, likely to get some tough safety questions on Kynamro at this week's FDA panel. More | Follow @JohnCFierce

 @RyanMFierce: Piramal is poised to be a big consolidator in pharma services/manufacturing, but apparently only at the right price. More | Follow @RyanMFierce

> FDA frets over safety of Genzyme's rival drug for rare cholesterol disease. Article

> Bullish Roche talks targeted takeovers, showcases T-DM1's prospects. Story

> ArQule, Threshold get a bounce out of PhIII SPA pacts with FDA. Report

Pharma News

@FiercePharma: Other compounded drugs may be tied into meningitis outbreak, FDA says. Another NECC steroid + NECC heart drug. More | Follow @FiercePharma

> J&J credits Remicade, Zytiga for 7% hike in Q3 drug sales. Story

> Roche sales hike sums up pharma hopes for cancer, emerging markets. Article

> India kicks branded generics to the curb. Report

Biotech Research News

> NIH funds Advanced Cancer Therapeutics' preclinical brain cancer drug work. Report

> Scientists flee $3B Texas cancer research fund. Item

> Alnylam, Tel Aviv U develop RNAi drugs to fight rare blood cancer. Article

> Alzheimer's drug builds new brain cell connections in rats. News

> Scientists build neural-like stem cells from mouse muscle tissue. Story

Pharma Manufacturing News

> GSK cancels plans to close Stiefel plant in Ireland. Story

> Cinven continues generics deal spree with Amdipharm buy. Article

> Teva Pharma opens $110M plant in Hungary. News

> Analysis: Compounding groups fought FDA oversight before NECC disaster. Report

 

Suggested Articles

Emmecell aims to make corneal transplant surgery, which can take up to a year to heal from and fails up to 20% of the time, a relic of the past.

Seven developers will provide digital health solutions aimed at the COVID-19 pandemic, including smartphone apps, wearables and big data programs.

Illumina will drop $8 billion to reacquire its former spinout, which after nearly five years is nearing completion of its cancer-seeking blood test.